main inclusion criteria: 1. first onset of covid-19 symptoms \<7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. 2. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. 3. male or female patients ≥18 years of age at the time of signing informed consent. 4. agree to use an adequate method of contraception throughout the study period and for 90 days after the dose of study drug is administered. 5. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main

main inclusion criteria: 1. first onset of covid-19 symptoms \<7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. 2. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. 3. male or female patients ≥18 years of age at the time of signing informed consent. 4. agree to use an adequate method of contraception throughout the study period and for 90 days after the dose of study drug is administered. 5. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main

main inclusion criteria: first onset of covid-19 symptoms <7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. male or female patients ≥18 years of age at the time of signing informed consent. agree to use an adequate method of contraception throughout the study period and for 90 days after the dose of study drug is administered. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main

main inclusion criteria: first onset of covid-19 symptoms <7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. male or female patients ≥18 years of age at the time of signing informed consent. agree to use an adequate method of contraception throughout the study period and for 90 days after the dose of study drug is administered. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main